Price
No data yet.
Social Signal Score
Analyst Ratings
20 analystsRevenue
$350.51M+1474.76%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Pete Anevski
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- Employees
- 846
- Beta
- 0.99
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 7.86
Financials
Revenue
$350.51M+1474.8%Net Income
$28.05MEBITDA
$44.24MFree Cash Flow
$83.81MEPS (diluted)
$0.34Shares Outstanding (diluted)
82.14M+1343.6%Operating Expenses
$49.30MCash & Debt
$236.93MReturn of Capital
$148.63MRevenue by Segment (annual)
$1.29BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.29B | $58.52M | $0.68 |
| 2024 | $1.17B | $54.34M | $0.59 |
| 2023 | $1.09B | $62.04M | $0.65 |
| 2022 | $786.91M | $30.36M | $0.33 |
| 2021 | $500.62M | $65.77M | $0.74 |
| 2020 | $344.86M | $46.46M | $0.54 |
| 2019 | $229.68M | $-8.57M | $-0.10 |
| 2018 | $105.40M | $661.0K | $0.01 |
| 2017 | $48.58M | $-12.45M | $-2.19 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.01
- Implied price
- $38.34
- Return from $25.23
- 8.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $19.06 — -24.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 26 | 32 | 38 | 44 | 50 |
|---|---|---|---|---|---|
| -2.0% | -8.6% | -4.7% | -1.3% | 1.6% | 4.2% |
| 3.0% | -3.9% | 0.2% | 3.7% | 6.8% | 9.5% |
| 8.0% | 0.8% | 5.1% | 8.7% | 12.0% | 14.9% |
| 13.0% | 5.4% | 9.9% | 13.8% | 17.1% | 20.2% |
| 18.0% | 10.1% | 14.8% | 18.8% | 22.3% | 25.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100-23.08%Social Signal Score
Mentions (6)
- Newszacks.com·17d ago·Neutral
PGNY vs. CRL: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027 Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY's Q2 2026 results highlight 11% revenue growth ex-Amazon, margin expansion, and nearly 100% EPS growth guidance for 2026, supporting a continued buy rating. Secular tailwinds—rising infertility rates, delayed family formation, and underpenetrate…
View source ↗ - Newszacks.com·26d ago·Neutral
Wall Street Analysts Predict a 25.23% Upside in Progyny (PGNY): Here's What You Should Know The mean of analysts' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Progyny, Inc. to Present at the Wells Fargo Healthcare Conference NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET.
View source ↗ - Newsmarketbeat.com·51d ago·Neutral
Progyny Sees Utilization Rebound as Early Renewals De-Risk Outlook Progyny NASDAQ: PGNY CEO Pete Anevski said the company expects member engagement and utilization to rebound following a more pronounced summer seasonal slowdown, while early renewal and new-client commitments have increased management's confidence in its outlook for the remainder of the year.
View source ↗ - Newsgurufocus.com·55d ago·Positive
Progyny Inc (PGNY) Stock Down 4.6% -- Now Undervalued? GF Score: 93/100 On August 11, 2026, Progyny Inc (PGNY) shares fell by 4.6%, bringing the current price to $26.55. The stock has seen significant volatility, with a 52-week high
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.31 per share
Typical surprise +7.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.36 vs $0.33beat
- Thu, May 7$0.30 vs $0.26beat
- Thu, Feb 26$0.15 vs $0.15beat
- Thu, Nov 6$0.16 vs $0.39miss
- Thu, Aug 7$0.20 vs $0.17beat
- Thu, May 8$0.18 vs $0.19miss
Estimates and results for PGNY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PGNY officers and directors.
- Bought
- $1.9m
- Sold
- $2.3m
1 trade
21 trades
- Swartz Allisonsold
- Gordon Kevin Ksold
- Gordon Kevin Ksold
- Cummings Melissa Bsold
- Livingston Mark S.sold
- Livingston Mark S.sold
- Swartz Allisonsold
- Swartz Allisonsold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 14, 2025 (39d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Aug 19, 2020 (20d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jul 17, 2020 (17d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 16, 2020 (15d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 16, 2020 (26d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.